Women’s Health Dx
Sera Prognostics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov. 1, 2019 -- Sera Prognostics will be presenting at the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Thursday, December 5th at 12:30 p.m. ET. Read More >
Sera Prognostics to Present at the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum
Oct. 21, 2019 -- Sera Prognostics announced that Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will be presenting at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum at the Westin Grand Central Hotel in New York City on Thursday, November 21st, at 3:00 p.m. ET Read More >
SERA PROGNOSTICS COMPLETES ENROLLMENT FOR PREVENT PTB CLINICAL INTERVENTION STUDY USING PreTRM® TEST
Feb. 19, 2019 -Sera announced that investigators at Intermountain Healthcare in Salt Lake City, UT, have ended enrollment into the PREVENT PTB study and final results are projected to be read-out before year-end 2019. Read More >
Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications
Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.